Skip to main content

OTC Markets Group Welcomes Vallant Financial Inc. to OTCQX

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Vallant Financial Inc. (OTCQX: VLNT), the holding company for Vallant Bank, has qualified to trade on the OTCQX® Best Market. Vallant Financial Inc. is now trading on OTCQX under the symbol “VLNT.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. The OTCQX Market serves as a more efficient and cost-effective public market for U.S. regional and community banks through standards tailored for bank reporting. By providing price transparency and broader information distribution, OTCQX enables banks to maximize the value of being a public company. To qualify for OTCQX, community banks...

Continue reading

Wix Announces Preliminary Results of Modified Dutch Auction Tender Offer

NEW YORK, April 2, 2026—Wix.com Ltd. (Nasdaq: WIX) (“Wix” or the “Company”) today announced the preliminary results of its “modified Dutch Auction” tender offer, which expired at one (1) minute after 11:59 P.M., New York City time, on April 1, 2026.  Based on the preliminary count by Equiniti Trust Company, LLC, the depositary for the tender offer (the “Depositary”), a total of 18,718,009 of Wix’s ordinary shares, par value NIS 0.01 per share (each, a “Share,” and collectively, the “Shares”), were properly tendered and not properly withdrawn at or below the purchase price of $92.00 per share. In accordance with the terms and conditions of the tender offer, and based on the preliminary count by the Depositary, Wix expects to accept for payment a total of 18,718,009 Shares, representing all Shares that were properly tendered and not properly...

Continue reading

Lightbridge to Participate at Upcoming Investor Conferences

RESTON, Va., April 02, 2026 (GLOBE NEWSWIRE) — Lightbridge Corporation (“Lightbridge” or the “Company”) (Nasdaq: LTBR), an advanced nuclear fuel technology company, today announced that President and CEO Seth Grae will present at three upcoming investor conferences in April 2026. Jefferies Virtual Nuclear Conference — Wednesday, April 8, 2026Seth Grae will deliver a presentation at 8:45 a.m. ET. The virtual event brings together companies across the nuclear energy and uranium sectors to discuss industry growth and strategic developments. Interested parties should contact their Jefferies representative to obtain access to the webcast. Gabelli Funds 12th Annual Waste & Environmental Services Symposium — Thursday, April 9, 2026 | New York, N.Y.Seth Grae will deliver a presentation at 2:00 p.m. ET. The symposium convenes institutional...

Continue reading

Alamos Gold Provides Notice of First Quarter 2026 Results and Conference Call, and Annual General Meeting of Shareholders

All amounts are in United States dollars, unless otherwise stated. TORONTO, April 02, 2026 (GLOBE NEWSWIRE) —  Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) plans to release its first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Senior management will host a conference call on Thursday, April 30, 2026 at 11:00 am ET to discuss the results. The Company will hold its 2026 Annual General Meeting of Shareholders (the “Annual Meeting”) on Thursday, May 28, 2026. Notice of First Quarter 2026 Results and Conference Call Participants may join the conference call via webcast or through the following dial-in numbers: Via Webcast: To view the live webcast, please register at www.alamosgold.com, or through the following link view webcast. Via Phone:         Toronto and International: (647)...

Continue reading

Roundtable and RYVYL Announce Shareholders Approve Merger, with 99% of Votes Cast in Favor

Seattle, WA, April 02, 2026 (GLOBE NEWSWIRE) — RYVYL Inc. (NASDAQ: RVYL) (“RYVYL” or the “Company”), and RTB Digital Inc.’s (Roundtable) CEO, James Heckman, announced today that the merger was approved at the Company’s Special Meeting of Shareholders held on April 1, 2026. The approval removes the final corporate hurdle to complete the merger, and, subject to Nasdaq approval of Roundtable’s initial listing application, which has been filed, establishes the foundation to list the combined company on Nasdaq as RTB Digital Inc., expected to be listed under the ticker symbol RTB. The transaction is anticipated to consummate imminently. “We are grateful for the outcome of today’s Special Meeting and appreciate RYVYL stockholders’ support for the merger,” said Heckman, founder and CEO of Roundtable. “In anticipation of bringing...

Continue reading

Sfil: Annual Financial Report 2025 now available

Paris, April 02, 2026 ANNUAL FINANCIAL REPORT 2025 In accordance with the regulatory requirements in force, Sfil announces that the French version of its Annual Financial Report 2025 was filed with the Autorité des Marchés Financiers (AMF) on April 02, 2026, and that it can be obtained from its website: https://sfil.fr/resultats-et-publications/ The English version of the Annual Financial Report 2025 will be available around mid-April 2026 on the website: https://sfil.fr/en/results-and-publications/AttachmentRFA Sfil 2025 Communiqué mise à dispo EN

Continue reading

Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findings Patients in the TED studies demonstrated greater levels of proptosis improvement from baseline after the initial 12-week high-dose period than after the following 12-week low-dose period, supporting the benefit of deeper IgG suppression. The hyperthyroid patients in the TED studies showed similar response rates of thyroid hormone normalization to those seen in the batoclimab Phase 2 study in Graves’ disease Immunovant remains focused on rapid advancement of IMVT-1402 in multiple indicationsDURHAM, N.C., April 02, 2026 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases,...

Continue reading

Futu Announces Cash Dividend

HONG KONG, April 02, 2026 (GLOBE NEWSWIRE) — Futu Holdings Limited (“Futu” or the “Company”) (Nasdaq: FUTU), a leading tech-driven online brokerage and wealth management platform, today announced that its board of directors approved a cash dividend of US$0.325 per ordinary share, or US$2.6 per American Depositary Share (“ADS”), payable in U.S. dollars (the “Dividend”) to holders of ordinary shares and holders of ADSs of record as of the close of business on April 16, 2026, New York time. The aggregate amount of the Dividend will be approximately US$365 million. The Dividend to be paid to the Company’s ADS holders through the depositary bank will be subject to the terms of the deposit agreement. The payment date is expected to be on or around April 29, 2026 for holders of ordinary shares and holders of ADSs. About Futu Holdings Limited Futu...

Continue reading

Top Ships Announces Filing of 2025 Annual Report on Form 20-F

ATHENS, Greece, April 02, 2026 (GLOBE NEWSWIRE) — TOP Ships Inc. (the “Company”), an international owner and operator of modern, fuel efficient “ECO” tanker vessels, announced today that its annual report on Form 20-F for the year ended December 31, 2025 (the “Annual Report”) has been filed with the U.S. Securities and Exchange Commission (the “Commission”). The Annual Report may be accessed through the Company’s website, www.topships.org, or on the website of the Commission, www.sec.gov. About the Company TOP Ships Inc. is an international owner and operator of ocean-going vessels focusing on modern, fuel-efficient eco tanker vessels transporting crude oil, petroleum products (clean and dirty) and bulk liquid chemicals. For more information about TOP Ships Inc., visit its website: www.topships.org. Cautionary Note Regarding...

Continue reading

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic need LPP marks the fourth indication in brepocitinib’s expanding late-stage development program Multiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indication A seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its first subjects in March 2026DURHAM, N.C., April 02, 2026 (GLOBE NEWSWIRE) — Priovant today announced a new Phase 2b/3 clinical program...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.